Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting

Histopathology

Volumn 57, Issue 6, 2010, Pages 935-940

  Vergine, Marco ^a   Brunelli, Matteo ^a   Martignoni, Guido ^a   Brunello, Eleonora ^a   Miller, Keith ^b   Pecori, Sara ^a   Bersani, Samantha ^a   Chilosi, Marco ^a   Menestrina, Fabio ^a   Manfrin, Erminia ^a   Bonetti, Franco ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

AMERICAN SOCIETY OF CLINICAL ONCOLOGY; BREAST CARCINOMA; COLLEGE OF AMERICAN PATHOLOGISTS; HUMAN; IMMUNOHISTOCHEMISTRY; INFILTRATIVE LOBULAR BREAST CARCINOMA; LETTER; MEDICAL SOCIETY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 78650247659     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03716.x     Document Type: Letter

References (6)

1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 2009; 20; 1319-1329.
2. Brunelli M, Manfrin E, Martignoni G et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am. J. Clin. Pathol. 2008; 129; 907-911.
3. Viale G, Rotmensz N, Maisonneuve P et al. Lack of prognostic significance of 'classic' lobular breast carcinoma: a matched, single institution series. Breast Cancer Res. Treat. 2009; 117; 211-214.
4. Reis-Filho JS, Simpson PT, Jones C et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J. Pathol. 2005; 207; 1-13.
5. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N. Engl. J. Med. 2008; 358; 1409-1411.
6. Marchio C, Lambros MB, Gugliotta P et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 2009; 219; 16-24.